Xiang Luo

Exploiting selective aldo-keto reductase 1C3 inhibitors and beyond: recent advances and future directions in cancer therapy.

Conventional cancer therapy has long been confronted by significant challenges, particularly drug resistance. Aldo-keto reductase family 1 member C3 (AKR1C3), an enzyme markedly overexpressed in diverse human malignancies and critically implicated in tumor progression and therapy resistance, has emerged as an attractiv...